Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001373604-25-000086·AN2 Therapeutics, Inc.
Schedule 13D ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, par value $0.00001 per share · CUSIP: 037326105
Event date: 2025-05-28
- Filing-level shares
- 3,217,423
- Percent of class
- 10.7%
- BML Investment Partners, L.P.Reported CIK 0001373604
Shares: 3,217,423 · Class: 10.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001373604-25-000086
- Form type
- SCHEDULE 13D/A
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- May 30, 2025
- Reporting period
- May 28, 2025
- Description
- Schedule 13D beneficial ownership